Literature DB >> 15803

Plasma levels of real and "apparent" hydralazine in man and rat.

S B Zak, G Lukas, T G Gilleran.   

Abstract

Derivatization of hydralazine in plasma under acidic conditions yields values for the concentrations of "apparent" hydralazine that are dependent on the pH in the derivatization step. The results have been explained by postulating the existence of acid-hydrolyzable conjugates of unknown structure. These metabolites appear to be present in rat and human plasma after oral dosing. Procedures have been developed for the selective analysis of hydralazine or its acid-labile conjugates, and applied to measurements of plasma concentrations in rat and man.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 15803

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.922


  9 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

2.  Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.

Authors:  D D Shen; J P Hosler; R L Schroder; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

3.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

4.  Autoradiographic study of the distribution of [3H]- and [14C]-hydrallazine in the rat.

Authors:  J R Baker; G R Bullock; I H Williamson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

5.  Identification of hydrallazine and hydrallazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity.

Authors:  K D Haegele; A J McLean; P du Souich; K Barron; J Laquer; J L McNay; O Carrier
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

6.  Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.

Authors:  M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Pharmacokinetics of oral hydralazine in chronic heart failure.

Authors:  A Hanson; B W Johansson; B Wernersson; L A Wåhlander
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Effect of food on the absorption of hydralazine in man.

Authors:  R J Walden; R Hernandez; D Witts; B R Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Transplacental passage and breast milk concentrations of hydralazine.

Authors:  H Liedholm; E Wåhlin-Boll; A Hanson; I Ingemarsson; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.